A Clinical Study to Assess Preliminary Efficacy, Safety and Tolerability of HH-120 Nasal Spray in COVID-19 Patients
NCT ID: NCT05659602
Last Updated: 2024-10-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
111 participants
INTERVENTIONAL
2022-07-09
2023-01-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People
NCT06048393
Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19
NCT05069610
Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis
NCT05180500
Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild COVID-19
NCT05599919
Intranasal Lavage With Hypochlorous Acid Safely Reduces the Symptoms in the Ambulatory Patient With COVID-19.
NCT05950295
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HH-120 group
HH-120 Nasal Spray
HH-120 Nasal Spray
HH-120 Nasal Spray 8-10 times per day for 6 consecutive days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HH-120 Nasal Spray
HH-120 Nasal Spray 8-10 times per day for 6 consecutive days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants with mild COVID-19 with symptom onset≤5 days or asymptomatic COVID-19.
* Participants being able and willing to provide informed consent prior to any study-specific procedure.
Exclusion Criteria
* Participants within the pregnancy or breastfeeding period or plan to be pregnant during the study period.
* Participants requiring oxygen treatment (such as non-invasive ventilation, invasive mechanical ventilation, ECMO, etc.).
* Participants with nasal disease that is inconvenient or intolerant of nasal spray administration, or cannot use the nasal spray treatment.
* Participants with comorbid Malignancy or with a history of malignancy.
* Participants with active or uncontrolled systemic autoimmune disease.
* Insufficient function of key organs.
* Other reasons considered by the investigator to be unsuitable for the trial.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Ditan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ronghua Jin
Chief Physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Ditan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HH120-IIT-NS05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.